Hui Feng, MD, PhD
Assistant Professor
Boston University School of Medicine
Dept of Pharmacology & Experimental Therapeutics

MD, Beijing Medical University
PhD, University of Georgia
MS, Peking Union Medical College



Cancer Research: Dr. Feng is Director of the Laboratory of Zebrafish Genetics and Cancer Therapeutics. Dr. Feng’s research interests focus on identifying novel genes and pathways that are essential for MYC-related tumor transformation and progression, particularly for T-Lymphoblastic Lymphoma/Leukemia, Neuroblastoma and Breast Cancer. The research strategy of Dr. Feng’s research is to combine the analysis of human cancer cells with the genetic and imaging capacities of the zebrafish system.

Current research areas in Dr. Feng’s laboratory include:
1) To determine the molecular mechanisms underlying tumor cell intravasation and tumor progression.
2) To identify novel genes and pathways that, when mutated, delay the initiation and progression of MYC-related cancers.
3) To test the identified genes’ therapeutic potential in treating MYC-related cancers and to characterize their molecular relevance to MYC.

The long-term goal of Dr. Feng’s research is to discover novel molecular therapies to target critical components of MYC-driven oncogenic pathways, thus providing treatment alternatives that are more specific and less toxic.

2014-2017 St. Baldrick's Foundation: St. Baldrick Career Development Award
2013-2014 Karin Grunebaum Cancer Research Foundation: Grunebaum Faculty Fellowship
2013-2016 Boston University: Ralph Edwards Career Development Professorship
2012-2015 National Cancer Institute: Howard Temin Pathway to Independence Award in Cancer Research (R00)
2012-2013 American Cancer Society : American Cancer Society pilot Award
2009-2010 Stahl Family Charitable Foundation: Stahl Family Charitable Foundation Award
2009-2011 National Cancer Institute: Howard Temin Pathway to Independence Award in Cancer Research (K99)
2008 Harvard Partners in Health: Partners in Excellence Award
2005-2005 Cancer Research Institute: Postdoctoral Fellowship Award
2005 American Association for Cancer Research: American Association for Cancer Research Award - declined
2005-2008 Leukemia and Lymphoma Society: Special Fellow Award


Regulatory Role and Targetability of UFDI in MYC-drlven Leukemia
01/01/2018 - 12/31/2021 (PI)
American Cancer Society, Inc.

The Role of DLST in Leukemogenesis
08/15/2017 - 07/31/2019 (PI)
NIH/National Cancer Institute
1R56CA215059-01

Targeting DLST as a novel therapeutic approach for neuroblastoma
07/01/2017 - 06/30/2018 (PI)
St. Baldrick's Foundation


Targeting Elevated S1P1 Signaling as a Novel Therapeutic Approach for Triple-Negative Breast Cancer
07/01/2016 - 06/30/2018 (PI)
The Mary Kay Foundation


Targeting DLST as a Novel Therapeutic Approach for Neuroblastoma
07/01/2014 - 06/30/2017 (PI)
St. Baldrick's Foundation


Dissecting the regulatory role of DLST in MYC-driven Leukemogenesis
07/01/2015 - 12/31/2016 (PI)
Leukemia Research Foundation


Oncorequisite Genes in MYC-mediated Transformation
04/01/2012 - 03/31/2015 (PI)
NIH/National Cancer Institute
5R00CA134743-05




Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Lian H, Li D, Zhou Y, Landesman-Bollag E, Zhang G, Anderson NM, Tang KC, Roderick JE, Kelliher MA, Seldin DC, Fu H, Feng H. CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells. Haematologica. 2017 01; 102(1):e17-e21.View Related Profiles. PMID: 27758824; DOI: 10.3324/haematol.2016.154013;.
     
  2. Anderson NM, Li D, Peng HL, Laroche FJF, Mansour MR, Gjini E, Aioub M, Helman DJ, Roderick JE, Cheng T, Harrold I, Samaha Y, Meng L, Amsterdam A, Neuberg DS, Denton TT, Sanda T, Kelliher MA, Singh A, Look AT, and Feng H. The TCA Cycle Transferase DLST is Important for MYC-mediated Leukemogenesis. Leukemia. 2016.
     
  3. Harrison NR, Laroche FJ, Gutierrez A, Feng H. Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights. Adv Exp Med Biol. 2016; 916:335-69.View Related Profiles. PMID: 27165361; PMCID: PMC4933302; DOI: 10.1007/978-3-319-30654-4_15;.
     
  4. Harrold I, Carbonneau S, Moore BM, Nguyen G, Anderson NM, Saini AS, Kanki JP, Jette CA, Feng H. Efficient transgenesis mediated by pigmentation rescue in zebrafish. Biotechniques. 2016 Jan; 60(1):13-20. PMID: 26757807; PMCID: PMC4768720; DOI: 10.2144/000114368;.
     
  5. Srinivasan S, Chitalia V, Meyer RD, Hartsough E, Mehta M, Harrold I, Anderson N, Feng H, Smith LE, Jiang Y, Costello CE, Rahimi N. Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis. Angiogenesis. 2015 Oct; 18(4):449-62.View Related Profiles. PMID: 26059764; PMCID: PMC4600037; DOI: 10.1007/s10456-015-9468-3;.
     
  6. Huiting L, Laroche, FJF, Feng H. The Zebrafish as a Tool to Cancer Drug Discovery. Austin Journal of Pharmacology and Therapeutics. Austin Journal of Pharmacology and Therapeutics. Secaucus. 2015; 2(3):1069.
     
  7. Huiting LN, Laroche F, Feng H. The Zebrafish as a Tool to Cancer Drug Discovery. Austin J Pharmacol Ther. 2015; 3(2):1069.View Related Profiles. PMID: 26835511.
     
  8. Shivanna S, Harrold I, Shashar M, Meyer R, Kiang C, Francis J, Zhao Q, Feng H, Edelman ER, Rahimi N, Chitalia VC. The c-Cbl ubiquitin ligase regulates nuclear ß-catenin and angiogenesis by its tyrosine phosphorylation mediated through the Wnt signaling pathway. J Biol Chem. 2015 May 15; 290(20):12537-46.View Related Profiles. PMID: 25784557; PMCID: PMC4432275; DOI: 10.1074/jbc.M114.616623;.
     
  9. Gutierrez A, Feng H, Stevenson K, Neuberg DS, Calzada O, Zhou Y, Langenau DM, Look AT. Loss of function tp53 mutations do not accelerate the onset of myc-induced T-cell acute lymphoblastic leukaemia in the zebrafish. Br J Haematol. 2014 Jul; 166(1):84-90. PMID: 24690081; DOI: 10.1111/bjh.12851;.
     
  10. Anderson NM, Harrold I, Mansour MR, Sanda T, McKeown M, Nagykary N, Bradner JE, Lan Zhang G, Look AT, Feng H. BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. Leukemia. 2014 May; 28(5):1145-8. PMID: 24342948; PMCID: PMC4013222; DOI: 10.1038/leu.2013.377;.
     
Showing 10 of 22 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 22 publications over 12 distinct years, with a maximum of 4 publications in 2015 and 2016

YearPublications
19991
20032
20051
20072
20091
20102
20111
20122
20131
20141
20154
20164
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Cancer
Cancer Therapeutics
MYC
Tumor Intravasation
Zebrafish

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Education Mentor
  • Research / Scholarly Mentor
  • Work / Life Integration Mentor
Contact for Mentoring:


72 E. Concord St Silvio Conte (K)
Boston MA 02118
Google Map

617.638.4171
Download vCard

Feng's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (152) concept(s)
_
Co-Authors
See all (7) people
_
Similar People
See all (60) people
_
Same Department
Search Department